SLG
DCPH

Stanley-Laman Group’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Stanley-Laman Group’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,349
Closed -$420K – 299
2021
Q3 		$420K Buy
+12,349
New +$394K 0.05% 229

Other funds holding DCPH

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Stanley-Laman Group's DCPH Position: Q4 2021 in Review

Stanley-Laman Group sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q4 2021, closing a stake of 12,349 shares — an estimated $420K sold.

Stanley-Laman Group first reported a position in DCPH in Q3 2021 and held it in 1 quarter. The position peaked at $420K in Q3 2021. 140 funds tracked by Wall St. Rank hold DCPH as of Q4 2021.

  • Stanley-Laman Group reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Stanley-Laman Group sold 12,349 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $420K.
  • Stanley-Laman Group first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Stanley-Laman Group's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $420K in Q3 2021.
  • 140 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Stanley-Laman Group's 13F filing for Q4 2021, filed 25 Jan 2022.